# Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma

> **NCT01282476** · PHASE2 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 18 (actual)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Panobinostat with Rituximab

## Key facts

- **NCT ID:** NCT01282476
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-06
- **Primary completion:** 2013-08
- **Final completion:** 2014-08
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2017-05-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01282476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01282476, "Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01282476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*